These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 27704192

  • 1. A rare case of rectal carcinoma and prostate carcinoma with coexistent Paget's disease mimicking bone metastases in both 18F-FDG and 68Ga PSMA PET/CT.
    Sasikumar A, Joy A, Pillai MR, Raman V, Vasudevan A, Madhavan J.
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):173. PubMed ID: 27704192
    [No Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jan; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. 68Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli?
    Lengana T, Lawal IO, Boshomane TG, Popoola GO, Mokoala KMG, Moshokoa E, Maes A, Mokgoro NP, Van de Wiele C, Vorster M, Sathekge MM.
    Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
    [Abstract] [Full Text] [Related]

  • 4. Aspecific Uptake of 68GA-PSMA in Paget Disease of the Bone.
    Bourgeois S, Gykiere P, Goethals L, Everaert H, De Geeter FW.
    Clin Nucl Med; 2016 Nov; 41(11):877-878. PubMed ID: 27556795
    [Abstract] [Full Text] [Related]

  • 5. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.
    Acar E, Kaya GÇ.
    Clin Nucl Med; 2019 Jan; 44(1):53-54. PubMed ID: 30325820
    [Abstract] [Full Text] [Related]

  • 6. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT.
    Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougère C.
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
    [Abstract] [Full Text] [Related]

  • 7. [68Ga]PSMA-HBED-CC PET/CT to differentiate between diffuse bone metastases of prostate cancer and osteopoikilosis.
    Behrendt F, Krohn T, Mottaghy F, Verburg FA.
    Nuklearmedizin; 2016 Dec 06; 55(6):N64-N65. PubMed ID: 27922151
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy.
    Uprimny C, Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C, Haubner R, von Guggenberg E, Buxbaum S, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2018 Oct 06; 45(11):1873-1883. PubMed ID: 29766246
    [Abstract] [Full Text] [Related]

  • 9. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
    Raju S, Sharma A, Patel C, Sahoo R, Das CJ, Kumar S, Sharma A, Kumar R.
    Nucl Med Commun; 2020 Nov 06; 41(11):1183-1188. PubMed ID: 32796451
    [Abstract] [Full Text] [Related]

  • 10. Serous Cystadenoma of the Pancreas Showing Uptake on 68Ga PSMA PET/CT.
    Chan M, Schembri GP, Hsiao E.
    Clin Nucl Med; 2017 Jan 06; 42(1):56-57. PubMed ID: 27764044
    [Abstract] [Full Text] [Related]

  • 11. Comparison of 68Ga-PSMA-11 PET/CT with 11C-acetate PET/CT in re-staging of prostate cancer relapse.
    Regula N, Kostaras V, Johansson S, Trampal C, Lindström E, Lubberink M, Velikyan I, Sörensen J.
    Sci Rep; 2020 Mar 19; 10(1):4993. PubMed ID: 32193430
    [Abstract] [Full Text] [Related]

  • 12. Prostate-Specific Membrane Antigen-Negative Metastases-A Potential Pitfall in Prostate-Specific Membrane Antigen PET.
    Noto B, Auf der Springe K, Huss S, Allkemper T, Stegger L.
    Clin Nucl Med; 2018 Jun 19; 43(6):e186-e188. PubMed ID: 29659383
    [Abstract] [Full Text] [Related]

  • 13. Whole-Body Integrated [68Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference.
    Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, Kirchner J, Puellen L, Harke N, Radtke JP, Umutlu L, Hadaschik BA, Herrmann K, Forsting M, Wetter A.
    Mol Imaging Biol; 2020 Jun 19; 22(3):788-796. PubMed ID: 31482413
    [Abstract] [Full Text] [Related]

  • 14. Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases.
    Perez PM, Hope TA, Behr SC, van Zante A, Small EJ, Flavell RR.
    Clin Nucl Med; 2019 Jan 19; 44(1):e28-e32. PubMed ID: 30394930
    [Abstract] [Full Text] [Related]

  • 15. Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.
    Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M, Schlemmer HP, Afshar-Oromieh A.
    Eur J Nucl Med Mol Imaging; 2016 Jan 19; 43(1):70-83. PubMed ID: 26508290
    [Abstract] [Full Text] [Related]

  • 16. 68Ga-PSMA-Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate Cancer.
    de Jong AC, Smits M, van Riet J, Fütterer JJ, Brabander T, Hamberg P, van Oort IM, de Wit R, Lolkema MP, Mehra N, Segbers M, van der Veldt AAM.
    J Nucl Med; 2020 Nov 19; 61(11):1607-1614. PubMed ID: 32169916
    [Abstract] [Full Text] [Related]

  • 17. Can Ga-68 PSMA PET/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?
    Esen T, Kılıç M, Seymen H, Acar Ö, Demirkol MO.
    Eur Urol Focus; 2020 Mar 15; 6(2):218-220. PubMed ID: 31113757
    [Abstract] [Full Text] [Related]

  • 18. 68 Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.
    Hruby G, Eade T, Emmett L, Ho B, Hsiao E, Schembri G, Guo L, Kwong C, Hunter J, Byrne K, Kneebone A.
    Asia Pac J Clin Oncol; 2018 Aug 15; 14(4):343-346. PubMed ID: 29663686
    [Abstract] [Full Text] [Related]

  • 19. Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer.
    Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K, Dettmann K, Langkilde NC, Haarmark C, Fisker RV, Arp DT, Carl J, Jensen JB, Petersen LJ.
    Eur J Nucl Med Mol Imaging; 2018 Oct 15; 45(11):1884-1897. PubMed ID: 29876619
    [Abstract] [Full Text] [Related]

  • 20. Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.
    Parida GK, Tripathy S, Datta Gupta S, Singhal A, Kumar R, Bal C, Shamim SA.
    Clin Nucl Med; 2018 Apr 15; 43(4):248-249. PubMed ID: 29474196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.